Evidence map›Paper›PMID 32597077›Full record

ReviewSheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi2020

[Progress and analysis on the development of 2019-nCoV vaccine].

Zhuang Kang, Mei Tang

Abstract readReview
In one paragraph

Review in Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Zhuang KangCollege of Life Science, Leshan Normal University, Leshan, Sichuan 614000, P.R.China;Department of Biotechnology, Chengdu Institute of Biological Products, Chengdu 610000, P.R.China.
Mei TangCollege of Life Science, Leshan Normal University, Leshan, Sichuan 614000, P.R.China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As the COVID-19 pandemic is intensifying globally, more and more people are pinning their hopes on the development of vaccines. At present, there are many research teams who have adopted different vaccine technology routes to develop 2019-nCoV vaccines. This article reviews and analyzes the current development and research status of 2019-nCoV vaccines in different routes, and explores their possible development in the future.

Indexed as

BetacoronavirusCoronavirus InfectionsCOVID-19COVID-19 VaccinesHumansPandemicsPneumonia, ViralSARS-CoV-2Viral VaccinesCOVID-19 VaccinesViral Vaccines2019-nCoVattenuated live vaccineinactivated vaccinenucleic acid vaccinerecombinant protein vaccine

Identifiers

PMID32597077
PMCPMC10319570

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.